Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
| Revenue (TTM) | $79.58M |
| Gross Profit (TTM) | $25.82M |
| EBITDA | $14.88M |
| Operating Margin | 17.10% |
| Return on Equity | 26.50% |
| Return on Assets | 11.90% |
| Revenue/Share (TTM) | $24.77 |
| Book Value | $15.40 |
| Price-to-Book | 4.00 |
| Price-to-Sales (TTM) | 2.54 |
| EV/Revenue | 2.549 |
| EV/EBITDA | 11.57 |
| Quarterly Earnings Growth (YoY) | -34.30% |
| Quarterly Revenue Growth (YoY) | 11.00% |
| Shares Outstanding | $3.20M |
| Float | $1.49M |
| % Insiders | 36.40% |
| % Institutions | 33.07% |
Volatility is currently expanding
PDEX heads into fiscal Q1 earnings with strong medical-device sales and margin momentum, but customer concentration, a shrinking backlog and acquisition risks loom.
Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
PDEX, APH and RELY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 18th, 2026.
PGY, OPHC, PDEX, TRV and HMN have been added to the Zacks Rank #1 (Strong Buy) List on September 18th, 2026.
Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality.
IRVINE, CA / ACCESS Newswire / April 30, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 third quarter ended March 31, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PDEX and any ticker you trade — then tracks every position and per-strategy win rate.
